Skip to Content
Merck
All Photos(1)

Key Documents

569250-U

Supelco

Discovery® HS C18 (3 µm) HPLC Columns

L × I.D. 5 cm × 4.6 mm, HPLC Column

Synonym(s):

Discovery RP18 HPLC Column

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
41115700
eCl@ss:
32110501
NACRES:
SB.52

product name

Discovery® HS C18 HPLC Column, 3 μm particle size, L × I.D. 5 cm × 4.6 mm

material

stainless steel column

Agency

suitable for USP L1

product line

Discovery®

feature

endcapped

manufacturer/tradename

Discovery®

packaging

1 ea of

extent of labeling

20% Carbon loading

parameter

≤70 °C temp. range
400 bar pressure (5801 psi)

technique(s)

HPLC: suitable
LC/MS: suitable

L × I.D.

5 cm × 4.6 mm

surface area

300 m2/g

surface coverage

3.2 μmol/m2

impurities

<10 ppm metals

matrix

silica gel, high purity, spherical particle platform
fully porous particle

matrix active group

C18 (octadecyl) phase

particle size

3 μm

pore size

120 Å

operating pH range

2-8

application(s)

food and beverages

separation technique

reversed phase

Looking for similar products? Visit Product Comparison Guide

Application


  • A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies.: This study developed a robust RP-HPLC method to determine molnupiravir in various nanoformulations, showcasing its potential application in permeability studies and ensuring drug stability (Reçber et al., 2022) (Reçber et al., 2022).

  • Analysis of terizidone in plasma using HPLC-UV method and its application in a pharmacokinetic study of patients with drug-resistant tuberculosis.: This research presented an HPLC-UV method for analyzing terizidone in plasma, facilitating its use in pharmacokinetic studies of patients with drug-resistant tuberculosis (Mulubwa and Mugabo, 2018) (Mulubwa and Mugabo, 2018).

  • Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.: The study optimized an LC method for quantifying doxorubicin in plasma and urine, crucial for pharmacokinetic, biomedical, and drug monitoring therapy applications (Maliszewska et al., 2018) (Maliszewska et al., 2018).

Features and Benefits

  • Stable, low bleed for LC-MS applications
  • Scalable from analytical to preparatory
  • Highly stable to ensure excellent run-to-run and lot-to-lot reproducibility
  • Higher hydrophobicity for better resolution of difficult analytes
   

Recommended products

Discover LiChropur reagents ideal for HPLC or LC-MS analysis

Legal Information

Discovery is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service